• Explore /
  • Poster
  • / Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

Abstract Poster

Authors

Ghassan Abou-Alfa

Ghassan K. Abou-Alfa

Memorial Sloan Kettering Cancer Center, New York, NY

Ghassan K. Abou-Alfa , Tim Meyer , Ann-Lii Cheng , Anthony B. El-Khoueiry , Lorenza Rimassa , Baek-Yeol Ryoo , Irfan Cicin , Philippe Merle , Joong-Won Park , Jean-Frédéric Blanc , Luigi Bolondi , Heinz Josef Klümpen , Stephen Lam Chan , Vincenzo Dadduzio , Colin Hessel , Anne E. Borgman-Hagey , Gisela Schwab , Robin Kate Kelley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01908426

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 207)

DOI

10.1200/JCO.2018.36.4_suppl.207

Abstract #

207

Poster Bd #

A4

Abstract Disclosures

Similar Posters

First Author: Robin Kate Kelley

First Author: Ghassan K. Abou-Alfa

First Author: Ghassan K. Abou-Alfa

First Author: Ghassan K. Abou-Alfa